Special Issue "Mild Cognitive Impairment"
Deadline for manuscript submissions: closed (10 February 2019)
Prof. Hiroyuki Shimada
Department for Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Japan
Website | E-Mail
Interests: Cohort study of geriatric syndromes 2; Community - based intervention research in elderly people with mild cognitive impairment; Safety driving in the older adults with cognitive impairments; Clinical research of preventing falls in long - term care settings
Prof. Hyuntae Park
Department of Health Care and Science, College of Health Science, Dong-A University, Korea
Interests: measurement and assessment of habitual physical activity and chronotype in geriatric epidemiological studies, and the development of senior-frendly information and communications technologies and comprehensive e-health assessment and program
The American Academy of Neurology updated its practice guidelines on mild cognitive impairment (MCI) in December 2017. The AAN concluded that: 1) MCI is common in older populations, and its prevalence increases with age and lower educational levels, 2) persons with MCI are at higher risk of progressing to dementia than age-matched controls, but 14.4%–55.6% of people diagnosed with MCI may return to neurologically intact, 3) no high-quality evidence exists to support pharmacologic treatments for MCI, and 4) clinicians should recommend regular exercise, discuss diagnosis, prognosis, long-term planning, the lack of effective medicine options (Level B), and they may recommend cognitive training and biomarker research to patients with MCI and families (Level C). The guideline panel also recommended the following research: 1) the use of consistent diagnostic criteria for MCI and dementia in clinical trials, to improve the ability to apply and combine results; 2) the inclusion of patient cohorts with specific biomarker data in treatment studies targeted at specific pathologies; 3) the use of outcome measures that are direct measures of clinically meaningful patient outcomes; and 4) study of early lifestyle and comorbidity modifications and the effects of such changes on the progression of MCI to different dementia subtypes. This Special Issue summarizes the recent understanding of diagnostic criteria for MCI and dementia, specific biomarker of MCI, outcomes in clinical trials, modifiable factor of reversion from MCI to cognitive normal, and update evidence of clinical trials in MCI.Prof. Hiroyuki Shimada
Prof. Hyuntae Park
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Mild cognitive impairment
- Alzheimer’s disease